Connected Drug Delivery Devices Market Size & Growth Forecast 2026–2035, By Segments (Application, Product Type, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Connected Drug Delivery Devices Market size stood at USD 8.39 Billion in 2025 and is predicted to grow at a 22.7% CAGR from 2026 to 2035, reaching USD 64.89 Billion by 2035. The industry revenue for 2026 is estimated at USD 10.12 billion.
Get more details on this report
Request Free Sample ReportConnected Drug Delivery Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America leads the market through strong adoption of digital healthcare, established reimbursement systems, and widespread integration of connected therapies into chronic disease management workflows.
- Asia Pacific is forecast to grow at a 24.97% CAGR as digital health adoption expands and healthcare providers increasingly deploy connected solutions for medication tracking and remote patient management.
Segment Momentum
- Diabetes Management accounted for 32.4% of the market in 2025, driven by the routine need for insulin delivery, dose tracking, adherence monitoring, and continuous patient engagement.
- Integrated Devices are expanding fastest because they combine drug delivery and connectivity in one system, simplifying treatment while enabling consistent data transmission and easier integration into routine care workflows.
Market Expansion Drivers
- Rising demand for remote patient monitoring accelerating adoption of connected medication devices.
- Increasing focus on medication adherence driving integration of smart dosing and reminder technologies.
- Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Key players in the connected drug delivery devices market include Medtronic plc (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Koninklijke Philips N.V. (Netherlands), Ypsomed Holding AG (Switzerland), Biocorp Production S.A. (France), Propeller Health (United States), Adherium Limited (New Zealand), Amiko Digital Health Ltd. (Switzerland), Phillips-Medisize LLC (United States), Cohero Health Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As care delivery shifts toward home-based management of chronic conditions, providers are placing greater value on devices that transmit dosing activity, usage patterns, and treatment status without requiring in-person follow-up. In the connected drug delivery devices market, this is driving demand for injectors, inhalers, and infusion-related platforms that can feed data into remote monitoring workflows, allowing clinicians to identify missed doses, improper use, or early signs of therapy disruption. Procurement decisions increasingly favor products that combine drug administration with digital visibility, since remote oversight improves continuity of care while helping health systems manage larger patient populations outside traditional settings.
Increasing focus on medication adherence driving integration of smart dosing and reminder technologies
Payers, providers, and pharmaceutical companies are giving more attention to whether patients follow prescribed regimens, especially in long-term therapies where missed or mistimed doses weaken outcomes and increase downstream costs. That pressure is influencing market adoption in the connected drug delivery devices market by pushing manufacturers to embed reminder alerts, dose logging, usage confirmation, and app-linked adherence support directly into delivery systems. The commercial appeal of these features comes from their practical role in reducing patient drop-off and generating actionable adherence data, which makes connected devices more attractive not only as administration tools but also as platforms for ongoing therapy management.
Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems
Partnerships between device makers, digital health companies, software developers, and diabetes care stakeholders are reshaping how products are positioned and used in routine treatment. In the connected drug delivery devices market, these collaborations are supporting market development by linking insulin delivery hardware with glucose data platforms, companion apps, and decision-support tools, creating more integrated care experiences than standalone devices can offer. This ecosystem approach influences purchasing and adoption because healthcare providers and users increasingly prefer solutions that fit into a broader diabetes management workflow, while manufacturers gain faster access to interoperability capabilities and established user networks through collaboration rather than internal development alone.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising demand for remote patient monitoring accelerating adoption of connected medication devices | 2.00% | High | North America, Europe | High | Near Term |
| Increasing focus on medication adherence driving integration of smart dosing and reminder technologies | 1.90% | High | North America, Asia Pacific | High | Mid Term |
| Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems | 1.60% | Moderate | North America, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the largest regional market share in 2025 for the connected drug delivery devices market, supported by broad uptake of digitally enabled care models, established reimbursement structures, and stronger integration of connected therapies into routine chronic disease management. The region’s leadership is aided by higher adoption of insulin delivery, remote monitoring, and app-linked adherence tools across provider networks that are already equipped to use patient-generated treatment data in everyday care decisions. This operating environment helps device manufacturers and healthcare systems move connected products beyond pilot use into regular clinical workflows.
Asia Pacific is projected to expand at a 24.97% CAGR over the forecast period, with growth in the connected drug delivery devices market being propelled by faster digital health adoption and rising deployment of connected care solutions across large patient populations. Demand is accelerating as healthcare providers and patients increasingly use mobile-first health platforms that can support medication tracking, adherence monitoring, and remote follow-up in practical, scalable ways. As access to connected technologies broadens across the region, adoption is being driven by the need to manage treatment delivery more efficiently in high-volume care settings.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Care AdoptionGermany emphasizes connected drug delivery devices that support structured disease management and secure health data exchange. Manufacturers focus on interoperable solutions aligned with digital healthcare initiatives while providers seek reliable patient adherence and therapy monitoring capabilities.
France 🇫🇷
Patient Monitoring FocusFrance supports connected drug delivery devices through initiatives that enhance chronic disease monitoring and coordinated patient care. Healthcare stakeholders increasingly value solutions that improve treatment compliance while fitting established clinical workflows.
Italy 🇮🇹
Home Therapy SupportItaly is expanding the use of connected drug delivery devices to strengthen home-based treatment and outpatient care. Device suppliers emphasize intuitive operation, remote follow-up, and improved medication adherence for patients managing long-term conditions.
Japan 🇯🇵
Aging Care ConnectivityJapan advances connected drug delivery devices to improve medication adherence among its aging population. Companies prioritize compact, user-friendly systems with remote monitoring functions that complement home-based care and long-term disease management programs.
South Korea 🇰🇷
Smart Health EcosystemSouth Korea integrates connected drug delivery devices with advanced digital health infrastructure and mobile healthcare platforms. Local innovation focuses on connected therapies, real-time patient engagement, and secure data sharing to improve treatment continuity.
United States 🇺🇸
Digital Therapeutics IntegrationThe U.S. prioritizes connected drug delivery devices that integrate with remote patient monitoring platforms and electronic health records. Healthcare providers and manufacturers emphasize adherence tracking, real-world data collection, and value-based care initiatives across chronic disease management.
Segment Leadership and Growth Trends
Connected Drug Delivery Devices Market Share (%), Application, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDiabetes Management held a 32.4% share of the connected drug delivery devices market in 2025, reflecting its established lead as the most commercially active application area and its continued growth momentum. This position is sustained by the routine, high-frequency nature of insulin administration and dose tracking, which creates a clear need for connected devices that support adherence, monitoring, and day-to-day treatment adjustments. The same practical care requirements are also driving faster expansion in this segment of the connected drug delivery devices market, as diabetes therapy depends heavily on consistent data capture and user engagement in a way that is more embedded in regular patient management than many other applications.
Product Type Segment Analysis: Integrated Devices (Largest & Fastest-Growing Segment)
Within the connected drug delivery devices market, Integrated Devices represented the leading product type in 2025, holding the largest share and continuing to expand at the fastest pace. Their market strength comes from the operational advantage of combining drug delivery and connectivity in a single system, which simplifies usage, reduces reliance on separate add-on components, and supports more consistent data transmission during routine treatment. That same built-in convenience is also accelerating adoption in the connected drug delivery devices market, as healthcare providers and users increasingly favor solutions that fit directly into existing administration workflows without added setup complexity.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Asthma, COPD, Diabetes Management, Others | Diabetes Management | Diabetes Management |
| Product Type | Standalone Components & Software, Integrated Devices | Integrated Devices | Integrated Devices |
| Route of Administration | Parenteral, Inhalational | Inhalational | Inhalational |
Competitive Landscape and Market Positioning
1. Medtronic plc (Ireland)
2. Teva Pharmaceutical Industries Ltd. (Israel)
3. Koninklijke Philips N.V. (Netherlands)
4. Ypsomed Holding AG (Switzerland)
5. Biocorp Production S.A. (France)
6. Propeller Health (United States)
7. Adherium Limited (New Zealand)
8. Amiko Digital Health Ltd. (Switzerland)
9. Phillips-Medisize LLC (United States)
10. Cohero Health Inc. (United States)
The connected drug delivery devices market is evolving through deeper integration of digital monitoring and patient-centric delivery systems. Growing emphasis on treatment adherence and remote tracking is accelerating smart healthcare connectivity. Continuous development efforts are focused on improving usability while strengthening real-time data-driven treatment support.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Nemera | Sep-22 | Nemera inaugurated a new facility in Lyon, France, intended to serve as its European headquarters and innovation center. The site strengthens the company’s R&D and industrial capabilities in drug delivery device development, supporting broader commercialization of connected and advanced delivery systems through enhanced engineering, prototyping, and operational integration in Europe. |
| Enable Injections | May-25 | Enable Injections received EU MDR CE mark approval for its enFuse Syringe Transfer System, enabling commercialization across European markets. The certification supports regulatory expansion of its large-volume subcutaneous delivery platform, strengthening the company’s position in advanced drug administration technologies and facilitating broader adoption of connected and patient-centric injectable delivery solutions. |
| Supernus Pharmaceuticals | Feb-25 | Supernus Pharmaceuticals received FDA approval for ONAPGO, a subcutaneous apomorphine infusion device for Parkinson’s motor fluctuations. The approval marks a significant commercialization milestone, expanding treatment options in neurological drug delivery and strengthening Supernus’s presence in device-enabled therapeutic solutions for chronic neurodegenerative disease management. |
| Gerresheimer | Dec-24 | Gerresheimer obtained FDA tentative approval for Lasix ONYU, a home-use furosemide micropump designed for congestive heart failure management. The development enhances Gerresheimer’s position in digitally enabled drug delivery systems, supporting the shift toward at-home infusion therapies and expanding its portfolio of connected and patient-managed drug delivery solutions. |
| Medtronic | Nov-24 | Medtronic received FDA clearance for its InPen app featuring missed-meal detection, integrated with its CGM ecosystem. The update strengthens Medtronic’s digital diabetes management portfolio by enhancing data-driven insulin dosing support, reinforcing its position in connected drug delivery ecosystems that integrate devices, sensors, and software platforms for chronic disease management. |
| Aptar Pharma | Jan-20 | Aptar Pharma partnered with Lupin Limited to launch ADHERO, India’s first connected metered-dose inhaler add-on device. The solution enables real-time tracking of inhaler usage for respiratory patients, strengthening adherence monitoring capabilities and expanding Aptar Pharma’s presence in connected respiratory drug delivery solutions within emerging markets. |
| Propeller Health | May-20 | Propeller Health received FDA 510(k) clearance to connect Symbicort inhaler users to its digital health platform. The clearance enabled expanded integration of inhaled therapies with digital monitoring systems, strengthening Propeller’s role in connected respiratory care and improving patient adherence and outcome tracking in chronic respiratory disease management. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Connected Drug Delivery Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Connected Drug Delivery Devices Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow large is the connected drug delivery devices market?
What is the anticipated CAGR of the connected drug delivery devices industry?
How is the expansion of remote patient monitoring shaping demand for connected drug delivery devices?
Why is integration between digital platforms and drug delivery devices accelerating diabetes care adoption?
Why does Diabetes Management lead the connected drug delivery devices market?
Why are Integrated Devices the fastest-growing product type in the connected drug delivery devices market?
Why does North America hold the largest share of the connected drug delivery devices market?
What is driving rapid growth in the connected drug delivery devices market across Asia Pacific?
Who holds a significant market share in the connected drug delivery devices landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization